- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
EP: 1.Understanding EGFR Mutations and First-Line Treatment
EP: 2.Overcoming Resistance Mechanisms and Addressing Unmet Needs
EP: 3.Impact of Recent Approvals and Novel Mechanisms
EP: 4.CNS Penetration and Efficacy of Emerging Therapies
EP: 5.Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
EP: 6.Sequencing Therapies and Using the Most Effective Options First
Panelists discuss how effective management of adverse events (AEs) supports successful integration of novel EGFR-targeted combinations like amivantamab and lazertinib. They review toxicity profiles across therapies, noting dermatologic and infusion-related reactions as common concerns. Strategies such as early recognition, prophylactic care, and multidisciplinary support are highlighted for minimizing discontinuation rates and maintaining adherence. The discussion emphasizes that proactive AE management enhances tolerability and patient confidence, ensuring long-term therapy success.
Preventing Tomorrow’s High-Cost Claims: The Rising-Risk Patient Opportunity in Medicaid
November 6th 2025For Medicaid care management, focusing on rising-risk patients is more effective than targeting high-cost claimants, whose spending tends to decrease over time due to regression to the mean.
Read More
